-
Consumer Insights
KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018
This KOL Insight briefing focuses on KOLs views of Pipeline Therapy Data Presented at EULAR 2018
-
Product Insights
Birch Pollen Allergy Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Birch Pollen Allergy Global Clinical Trials Review, H2, 2018" provides an overview of Birch Pollen Allergy clinical trials scenario. This report provides top line data relating to the clinical trials on Birch Pollen Allergy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Competitor Landscape: Graft Versus Host Disease (GVHD)
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the graft versus host disease (GVHD) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Competitor Landscape: Sjögren's Syndrome
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Sjögren's Syndrome market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Competitor Landscape: Systemic Sclerosis (Scleroderma)
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Systemic Sclerosis (Scleroderma) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Product Insights
Pollen Allergy Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Pollen Allergy Global Clinical Trials Review, H1, 2018" provides an overview of Pollen Allergy clinical trials scenario. This report provides top line data relating to the clinical trials on Pollen Allergy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Consumer Insights
KOL Perspectives: Biomarker Potential of Type I IFN Gene Signature in Lupus
› This KOL Insight briefing focuses on the IFN gene signature as a potential biomarker in Lupus
-
Product Insights
Ragweed Pollen Allergy Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Ragweed Pollen Allergy Global Clinical Trials Review, H1, 2018" provides an overview of Ragweed Pollen Allergy clinical trials scenario. This report provides top line data relating to the clinical trials on Ragweed Pollen Allergy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Cat Allergy Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Cat Allergy Global Clinical Trials Review, H2, 2018" provides an overview of Cat Allergy clinical trials scenario. This report provides top line data relating to the clinical trials on Cat Allergy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Sjögren’s Syndrome (SS) is a chronic and systemic autoimmune inflammatory disorder in which an initial immunological attack that primarily targets the lacrimal and salivary glands and results in keratoconjunctivitis sicca (KCS [dry eye disease]) and/or stomatitis sicca (dry mouth disease). Though sometimes referred to as “sicca syndrome,” referring to dryness of the exocrine glands, symptoms that most SS patients do display, a patient is only classified as having sicca when there is no evidence of the presence of an autoimmune...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.